February 22, 2010 3:31 PM
- Text
Blood Tests May Reveal Tumor Size
(CBS)
This article was written by Discover'sAndrew Moseman.
Doctors who are torn over how aggressively to treat a cancer patient, not knowing whether a tumor has fully regressed or is coming back, might someday be able to find out just by testing the patient's blood. In a study forthcoming his week in Science Translational Medicine,John Hopkins researchers say they have tested a way to spot the "fingerprint" of cancer-the changes to the likened the approach to drawing a map. Sequencing the letters of the genetic code would be akin to plotting every house in a large neighborhood. The Hopkins team was looking only for neighborhoods-in particular, neighborhoods out of place compared with where they would be in normal tissue. The researchers in the study looked at tissue from people with breast or bowel cancer, and found multiple DNA rearrangements in each of the samples of cancerous tissue.
In each patient, the genetic changes in the cancerous cells amount to a unique marker of the patient's tumor, the researchers say. Using blood samples from two of the colorectal cancer patients, they found the test was sensitive enough to detect this marker or "fingerprint" DNA that had been shed by tumors into the bloodstream.
The study's approach could be invaluable for tracking the progress of a tumor. When a cancer is operated on or treated with radio - or chemotherapy, the levels of the fingerprint should fall, and vanish altogether if the tumor has been eradicated. Indeed, in one of their patients, the study authors saw the cancer biomarker drop after surgery but then rise again, suggesting to them that the cancer wasn't fully eradicated.
Because the technique requires sequencing a person's whole genome, it's not coming to a hospital near you in the immediate future, says study author Bert Vogelstein: "This is really personalized medicine. This is not something off the shelf…. This is something that has to be designed for each individual patient". But with the cost of genome sequencing rapidly coming down in price, this kind of approach might not be too far away, and doctors could use it to catch a recurring cancer before it's large enough to be visible to other methods, like CT scans.
By Andrew Moseman
Reprinted with permission from Discover
Doctors who are torn over how aggressively to treat a cancer patient, not knowing whether a tumor has fully regressed or is coming back, might someday be able to find out just by testing the patient's blood. In a study forthcoming his week in Science Translational Medicine,John Hopkins researchers say they have tested a way to spot the "fingerprint" of cancer-the changes to the likened the approach to drawing a map. Sequencing the letters of the genetic code would be akin to plotting every house in a large neighborhood. The Hopkins team was looking only for neighborhoods-in particular, neighborhoods out of place compared with where they would be in normal tissue. The researchers in the study looked at tissue from people with breast or bowel cancer, and found multiple DNA rearrangements in each of the samples of cancerous tissue.
In each patient, the genetic changes in the cancerous cells amount to a unique marker of the patient's tumor, the researchers say. Using blood samples from two of the colorectal cancer patients, they found the test was sensitive enough to detect this marker or "fingerprint" DNA that had been shed by tumors into the bloodstream.
The study's approach could be invaluable for tracking the progress of a tumor. When a cancer is operated on or treated with radio - or chemotherapy, the levels of the fingerprint should fall, and vanish altogether if the tumor has been eradicated. Indeed, in one of their patients, the study authors saw the cancer biomarker drop after surgery but then rise again, suggesting to them that the cancer wasn't fully eradicated.
Because the technique requires sequencing a person's whole genome, it's not coming to a hospital near you in the immediate future, says study author Bert Vogelstein: "This is really personalized medicine. This is not something off the shelf…. This is something that has to be designed for each individual patient". But with the cost of genome sequencing rapidly coming down in price, this kind of approach might not be too far away, and doctors could use it to catch a recurring cancer before it's large enough to be visible to other methods, like CT scans.
By Andrew Moseman
Reprinted with permission from Discover
Popular Now in SciTech
- Apple iPad 3 rumors: thicker, sharper, coming soon
- Tesla's Model X: Finally, an electric car we all want
- Retro Duo will play your old Nintendo games
- Obama's 2012 campaign playlist now on Spotify
- FBI releases Steve Jobs background report
- iPad 3 mini on the way, says analyst
- Apple iPad 3 rumors resurface, sources say March release
- Apple iPhone 5 rumors, reports say June release
- Apple faces $1.6 billion iPad trademark lawsuit
- Hackers release Symantec pcAnywhere source code
- Facebook graffiti artist David Choe, from homeless to millions
- Apple supplier Foxconn hit by hackers
- Google developing home entertainment system
- Ethical iPhone 5 petitions head to Apple stores
- Apple iPad 3 rumors, let's get real
- Shocking Stats on Texting While Driving
- Facebook required for Spotify account, here's a trick
Latest CBS News Headlines
on Facebook Most Discussed Stories
on CBS News
- Wade scores 26, Bosh 24; Heat beat Wizards 106-89
- Great February getaways, for less
- Tyreke Evans leads Kings past Thunder
- Tyreke Evans leads Kings past Thunder
on Facebook Most Discussed Stories
on CBS News






